A Phaeohyphomycosis Case: A Rare Entity

  • Zekayi Kutlubay Department of Dermatology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Murat Küçüktaş Department of Dermatology, Nevşehir State Hospital, Nevşehir
  • Övgü Aydin Department of Pathology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Cuyan Demirkesen Department of Pathology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Burhan Engin Department of Dermatology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Ertuğrul H. Aydemir Department of Dermatology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Erkan Yilmaz Blood Bank, Tissue Typing Laboratory, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
  • Bülent Eren Council of Forensic Medicine of Turkey, Bursa Morgue Department, Bursa
Keywords: phaeohyphomycosis, black mould, itraconazole

Abstract

Phaeohyphomycosis is the term used to describe infections with darkly pigmented moulds appearing as septate filaments in host tissues. The disease is a histopathological rather than a clinical entity. A 79-year-old patient presented with multiple ulcerated lesions and nodules on the face. Microbiological culture identified the fungal isolate as phaeohyphomycosis. In the histopathological examination, granuloma formation with neutrophils in the center was detected due to infection. Oral daily 400 mg itraconazole was administered for 6 months. Follow-up at 12 months demonstrated no signs of infection. Clinical manifestations of cutaneous phaeohyphomycosis vary significantly. Although optimal treatment options remain contraversial, this case of phaeohyphomycosis was successfully treated by itraconazole monotherapy.

Downloads

Download data is not yet available.

References

Revankar SG. Dematiaceous fungi. Mycoses 2007; 50: 91–101.

Hay RJ, Ashbee HR. Mycology. In: Rook’s Textbook of Dermatology. Eds. Burns T, Breathnach S, Cox N, Griffiths C. 8thEdititon. West Sussex, Wiley-Blackwell, 36.77.

Ajello L, George LK, Steigbigel RT, Wang CJ. A case of Phaeohyphomycosis caused by new species of phialophora. Mycology 1974; 66: 490–498.

Russo JP, Raffaeli R, Ingratta SM, Rafti P, Mestroni S. Cutaneous and subcutaneous phaeohyphomycosis. Skinmed 2010; 8: 366–369.

Kwon–Chung KJ, Bennett JE. Phaeohyphomycosis. In: Medical Mycology. Pennsylvania: Lea & Feblger, 1992; 620–677.

Garnica M, Nucci M, Queiroz-Telles F. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009; 22: 559–563.

Ogawa MM, Galante NZ, Godoy P, Fischman--Gompertz O, Martelli F, Colombo AL, Tomimori J, Medina-Pestana JO. Treatment of subcutaneous phaeohyphomycosis and prospective follow-up of 17 kidney transplant recipients. J Am Acad Dermatol 2009; 61: 977–985.

Chandra J. Phaeohyphomycosis. In Medical Mycology. 2ndEd. Mehta Publication; 2003; p. 147–154.

McGinnis MR: Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol 1983; 8: 1–16.

Suh MK. Phaeohyphomycosis in Korea. Nippon Ishinkin Gakkai Zasshi 2005; 46: 67–70.

Silveira F, Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis. 2001; 14: 679–84.

Coldiron BM, Wiley EL, Rinaldi MG. Cutaneous phaeohyphomycosis caused by a rare fungal pathogen, Hormonema dematioides: successful treatment with ketoconazole. J Am Acad Dermatol. 1990; 23: 363–7.

Parente JN, Talhari C, Ginter-Hanselmayer G, Schettini AP, Eiras Jda C, de Souza JV et al. Subcutaneous phaeohyphomycosis in immunocompetent patients: two new cases caused by Exophiala jeanselmei and Cladophialophora carrionii. Mycoses. 2011; 54: 265–9.

How to Cite
1.
Kutlubay Z, Küçüktaş M, Aydin Övgü, Demirkesen C, Engin B, H. Aydemir E, Yilmaz E, Eren B. A Phaeohyphomycosis Case: A Rare Entity. TEST ZdravVestn [Internet]. 1 [cited 28Apr.2024];83(11). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/1314
Issue
Vol 83 No 11 (2014): November
Section
Case report, short scientific article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.